H.C. Wainwright & Co., LLC

Today and every day, we are thankful for the people and partnerships that drive our work forward. From all of us at H.C. Wainwright, Happy Thanksgiving.

Register now to attend our upcoming virtual fireside chat with CleanSpark management including S. Matthew Schultz, Co-founder, Executive Chairman, and CEO, Gary A. Vecchiarelli, CPA, President and CFO, and Harry Sudock, Chief Business Officer, to discuss the company’s recent expansion into HPC/AI data center development along with management’s outlook for CleanSpark’s BTC mining business. On the call, Mike Colonnese, CFA and the CleanSpark team will explore key areas of focus for investors including: a deep dive into management’s HPC/AI strategy, the suitability of CleanSpark’s existing power assets for HPC/AI conversion, time to market, and prospective customer demand. Register to attend live: https://lnkd.in/g-xU2NKk

Hear Oncolytics Biotech Inc. (NASDAQ: ONCY) CEO Jared Kelly discuss the company’s development strategy for Pelareorep and ongoing clinical work across GI cancers. HCW is proud to bring you access to corporate leaders to help keep our investors informed on industry developments. Register for access to the HCW Media Room to watch the full interview here: https://lnkd.in/gq3mJZuG Statements made in this interview reflect the views of the speaker and are based on information provided by the issuer. H.C. Wainwright & Co., LLC has not independently verified the clinical data or claims discussed. This communication is not research, investment advice, or a recommendation, and should not be relied upon as such. Any discussion of clinical programs is subject to risks, uncertainties, and ongoing regulatory review. This communication is for informational purposes only. It is not intended as an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Since H.C. Wainwright & Co., LLC is not a tax advisor, transactions requiring tax consideration should be reviewed carefully with your tax advisor. All market prices, data and other information are not guaranteed as to completeness or accuracy and are subject to change without notice. H.C. Wainwright & Co., LLC, Member FINRA, SIPC

Catch up on our weekly TRx tracker covering key published research and investor discussions across commercial names in our coverage universe. This week’s data marks the seventh full week of 4Q25. Read the full report here: https://lnkd.in/drtaGvnk

We are excited to introduce the HCW Crypto & AI Weekly Roundup, our newly refreshed weekly report capturing miners’ pivot to HPC/AI, power portfolios, and the metrics that matter most.   BTC is now down by over 25% from all-time highs reached in early October after correcting by another 10% last week to $94,182.    Read the full report here: https://lnkd.in/gNE_j-9Q

Last day to register for tomorrow's event, KOL Call on Advancements in Acute Pain Management, hosted by HCW's Douglas Tsao and Andrew Fein. We are pleased to host Dr. Vinod Dasa MD, a leading orthopedic surgeon, to discuss his approach to post-surgical pain management. Dr. Dasa has been able to meaningfully reduce use of opioids through the use of novel pain control agents, including Pacira BioSciences, Inc.'s (PCRX; Buy; Tsao) Exparel and Vertex Pharmaceuticals's (VRTX; Buy; Fein) Journavx. We will discuss the evolution of multimodal pain regimens and how the use of Journavx has furthered reduced opioid use. Register via the link here https://lnkd.in/dnvaCuyw

Hear Bit Digital | NASDAQ: BTBT and WhiteFiber (NASDAQ: WYFI) CEO Sam Tabar discuss the company’s origins, the evolution of its operations, and the strategic thinking behind WhiteFiber. Today, Bit Digital holds more than 150,000 ETH, underscoring its strong position in the digital asset landscape. HCW is proud to bring you direct access to the leaders and stories shaping their sectors. Watch the full interview here: https://lnkd.in/gVc_eTqz   This communication is for informational purposes only. It is not intended as an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Since H.C. Wainwright & Co., LLC is not a tax advisor, transactions requiring tax consideration should be reviewed carefully with your tax advisor. All market prices, data and other information are not guaranteed as to completeness or accuracy and are subject to change without notice H.C. Wainwright & Co., LLC., Member FINRA, SIPC

Register now for our upcoming KOL event, Biotech Breakthroughs: A Monthly Discovery Series with HCW's Patrick Trucchio. We are honored to host Dr. Martin Steinberg and Marilyn Telen to discuss the evolving treatment landscape of red blood cell (RBC) disorders, exploring novel and approved therapies including Beam Therapeutics (BEAM; Buy) Beam-101, an ex vivo cell therapy for sickle cell disease (SCD) with a data update for the Phase 1/2 BEACON trial expected in December, and BEAM-103 + BEAM-104, an antibody paired cell therapy for SCD and beta thalassemia, among others. Register via the link here https://lnkd.in/e7x8Pev6

We are proud to recognize Michael Meyers for contributing to an impactful weekend dedicated to patient advocacy and supporting those eligible for advanced cell and gene therapies. His participation underscores HCW’s commitment to thoughtful engagement across the life sciences community.

Traditional finance and crypto-native firms are clashing over how strictly the GENIUS Act should be interpreted. With the comment period now closed, the U.S. Treasury begins reviewing competing proposals, from strict stablecoin restrictions to narrower frameworks.    HCW Research provides their predictions on how the U.S. Treasury may rule. Read the full report here: https://lnkd.in/d8GMwdVw